For that reason, the biomarkers DPD and TP may possibly be candidates to choose no matter whether S-one or capecitabine be appropriate for each client
Recently, numerous scientific studies had targeted on the big difference between S-1-based and capecitabine-based mostly regimens. A preceding stage II review of capecitabine monotherapy in Japan showed an ORR of…